Paula Green, serving as Senior Vice President of Human Resources at Twist Bioscience Corp (NASDAQ:TWST), completed a transaction on June 22, 2026, involving the sale of 291 shares of the company's common stock. The aggregate value of this divestment stood at $25,410, with each share transacted at a price of $87.3224. Crucially, this sale was not a discretionary move but rather a mandatory mechanism to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units. Twist Bioscience's equity incentive plans explicitly require that such tax liabilities be settled through a "sell to cover" process, thereby insulating the transaction from personal investment sentiment.
Following the execution of these sales, Ms. Green maintains a direct ownership stake of 120,414 shares of Twist Bioscience common stock. The timing of this corporate event coincides with a period of significant price appreciation for TWST. The stock is currently trading at $91.35, a level near its 52-week high of $89.71. This valuation reflects a remarkable 168% surge in value year-to-date. Despite this upward trajectory, analysis from InvestingPro indicates that the stock's current price may exceed its Fair Value estimate, categorizing TWST among a list of companies deemed overvalued relative to intrinsic metrics.
Financial performance metrics underscore the company's recent momentum. Twist Bioscience reported second-quarter revenues totaling $111 million. This figure not only surpassed the consensus estimate of $108 million but also represented a 19% increase compared to the same period last year. The robust revenue beat prompted TD Cowen to raise its price target on the stock from $58 to $68, while maintaining a Buy rating. Furthermore, during an Investor Day presentation, Twist Bioscience management articulated ambitious long-term goals. The company expects revenue to reach approximately $1 billion by fiscal year 2031, driven by a compound annual growth rate exceeding 16%. This optimistic outlook led Leerink to increase its price target from $70 to $80, maintaining an Outperform rating.
Analyst sentiment has shifted markedly positive, with several firms initiating coverage. Canaccord Genuity started coverage with a Buy rating and a $90 price target, citing the company's innovative silicon-based technology. Piper Sandler initiated coverage with an Overweight rating and an $85 price target, emphasizing Twist's critical role in expanding DNA synthesis infrastructure, particularly as AI applications in biology grow. TD Cowen further raised its price target to $89 from $68, highlighting the company's capacity to meet increasing demands for AI-driven wet lab and data services. The stock closed at $91.34 after hours, reflecting a -0.01% change, while the day's trading saw a +7.47% gain.
- Key Point 1: The mandatory nature of the SVP's stock sale, driven by tax withholding rules for vested Restricted Stock Units, highlights standard corporate compliance rather than insider sentiment, leaving her direct holdings at 120,414 shares.
- Key Point 2: Twist Bioscience's financial trajectory shows strong growth, with Q2 revenues of $111 million beating estimates by $3 million and growing 19% year-over-year, supporting ambitious long-term revenue targets of $1 billion by 2031.
- Key Point 3: Analyst consensus has turned bullish, with multiple firms initiating coverage and raising price targets, citing the company's silicon-based technology and expansion in DNA synthesis infrastructure driven by AI biology applications.
- Risk 1: Valuation concerns persist, as TWST trades near its 52-week high and is identified by market analysis as potentially overvalued relative to Fair Value estimates, suggesting a disconnect between current price and intrinsic worth.
- Risk 2: The company's aggressive revenue growth projections, including a compound annual growth rate exceeding 16% toward a $1 billion target by fiscal year 2031, introduce execution risk if the company fails to meet increasing AI-driven wet lab and data demands.